INSIGHT REPORT CALENDAR

NEWSLETTER

Like this article?

Sign up to our free newsletter

Advent International submits binding offer for STADA Arzneimittel Aktiengesellschaft

Advent International has submitted a legally binding, fully financed offer to purchase all STADA shares to the management board of STADA Arzneimittel Aktiengesellschaft at a price of EUR58 per share.

Advent is convinced that this offer comes with high transaction security and is in the best interest of the company, its shareholders and its employees.
 
The binding offer, as well as the decision to make a voluntary public takeover offer for all shares of STADA, are subject to approval by the management board of STADA.
 
The offer price corresponds to a premium of around 66 per cent compared to the share price on 31 March 2016, before the share purchases of activist investors became public. It also implies a premium of around 26 per cent compared to the calculated volume-weighted three-month average share price before Advent first approached STADA with an indicative proposal on 1 February 2017.
 
Advent currently expects the transaction to close after the dividend payment for the business year 2016. Investors would therefore benefit from the expected dividend payment in addition to the cash offer price.
 
Advent says it would further boost STADA’s growth through investments in new products, line extensions and acquisitions. Advent has a firm commitment to STADA’s management, its long-term strategy and to Germany as a base for business and future investment. Advent has no intention to sell off significant parts of the business or to split the company.
 
Advent’s long-term strategy for STADA centres on developing new growth areas and the targeted acceleration of its international expansion. The geographic focus will be on markets where STADA already has a leading position, particularly Germany, Italy, Spain, the UK, Belgium and Russia. Advent has also identified additional growth potential through expansion and investments in Asia and Latin America.
 
Advent has access to additional capital for future acquisitions and will make its operational experience, sector expertise and global network available to support management in the execution of its strategy.
 
Advent International has been active in Germany for more than 25 years.
 
Since its foundation, Advent has completed over 35 investments in the healthcare sector worldwide, including in the fields of pharmaceuticals (Viatris – formerly Asta Medica, Grupo Biotoscana, LKM, Terapia, Tropon), pharmaceutical distribution (Mediq, Genoa), pharmaceutical outsourcing in sales and clinical research (inVentiv Health), services for health insurance companies (Cotiviti), and service providers and clinics (MEDIAN Kliniken, Priory, ATI Physical Therapy Holdings, American Heart of Poland, Casa Reha).

Like this article? Sign up to our free newsletter

FEATURED

Tech Stocks

MOST RECENT

FURTHER READING